The contrasting signals — executive selling while a known external investor buys — suggest divergent views. Monitor for upcoming earnings or clinical trial updates that may have prompted Lindstrom’s confidence. Watch for follow-up trades from other board members or executives.
Price Chart
Executive Summary
A cluster of insider transactions at Ocular Therapeutix (OCUL) shows mixed activity: one significant open-market purchase by external investor Richard L. Lindstrom for $461K, alongside coordinated open-market sales by five executives totaling $256K. The selling executives include the Chief Development Officer, Chief Scientific Officer, Chief Strategy Officer, Chief Medical Officer, and Pravin Dugel (role unspecified), all selling near the same price point.
Key Financial Metrics
Key Facts
- Richard L. Lindstrom purchased 60,229 shares at $7.66 for $461,354.14 on February 20, 2026.
- Five insiders sold a combined 31,192 shares across February 20 and 23, 2026, for $256,374.36 in total.
- Selling insiders include four C-suite executives: Peter Kaiser (CDO), Jeffrey Heier (CSO), Sanjay Nayak (CSO), and Nadia Waheed (CMO), plus Pravin Dugel.
- All transactions were open-market trades; no derivative exercises or grants involved.
- Sales occurred at prices between $7.74 and $8.28 per share, near recent market levels.
Financial Impact
Net selling of $256K by insiders, offset by $461K purchase from external investor Lindstrom; net positive cash flow of $205K into stock.
Risk Factors
- Coordinated executive selling may signal lack of confidence in near-term prospects despite strong external buying.
- Lindstrom’s purchase, while large, is from a non-corporate insider and may reflect personal conviction rather than fundamental catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (6 trades, 7d window) | cluster-OCUL-1772109078986 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access